Summary:diarrhoea induced by HSD-HDC. Prospective controlled trials are needed to confirm its value. Keywords: diarrhoea; high-dose chemotherapy; octreoEmphasis has been put on the intensification of chemotherapy programs through high-dose chemotherapy tide acetate regimens. While their myelosuppression is managed through the use of colony-stimulating factors and/or infusion of autologous peripheral blood progenitor cell Chemotherapy-related diarrhoea is a very common problem transfusions (PBPCT), extramedullary dose-limiting in cancer patients. Although diarrhoea has been reported toxicities, including gastrointestinal mucosal injury, are with many antineoplastic drugs, this adverse effect is usua treatment-limiting factor and their management is a ally associated with 5-FU, 1 CDDP 2 and most recently with critical issue in HSD-HDC. Octreotide is effective in the CPT 11. 3 The diarrhoea associated with high-dose chemocontrol of diarrhoea induced by fluoropyrimidines. We therapy is not only a quality of life issue, but often a lifehave studied its effect on hematopoietic support-depenthreatening toxicity. Mucosal injuries associated with dent high-dose chemotherapy (HSD-HDC) related diawatery diarrhoea result in dehydration, electrolyte disorders rrhoea. HSD-HDC-treated patients were included in the and can be a harbinger of sepsis and neutropenic infections, study when they had у4 loose stools per day. Diagnostic all events which may prolong hospitalization. The successwork-up included physical examination, stool culture, ful management of this toxicity will facilitate the developClostridium difficile toxin assay, abdominal plain films, ment of outpatient intensive chemotherapy programs. complete blood counts, liver and renal function tests.Octreotide acetate (Sandostatin; Sandoz Pharmaceutical, Patients were treated with 0.1 mg octreotide, q 8 h, subHanover, NJ, USA), a synthetic polypeptide analog of somcutaneously for 48 h. Responding patients (р2 loose atostatin, has proven to be safe and effective in the treatstools per day) continued treatment at the same dose ment of secretory diarrhoea associated with the Zollingerfor an additional 24 h. Lack of response (у3 loose stools Ellison syndrome, the carcinoid syndrome, the Vernerper day), led to dose escalation by 0.1 mg increments, Morrison syndrome, AIDS and graft-versus-host disease. 4-8up to a 0.5 mg/dose and the latter dose was maintained Furthermore, impressive results have been reported with for 24 h. Patients not responding at 0.5 mg/8 h were octreotide acetate in several studies involving 5-fluorouraconsidered failures. A consecutive cohort of 24 HSDcil 9,10 and cisplatin 11 -induced diarrhoea. In a randomized HDC treated patients was studied. Fourteen (n = 14) study in solid tumour patients treated with 5-fluorouracil (58.33%) patients developed severe diarrhoea with a who developed severe diarrhoea, octreotide showed superimedian number of 7.5 loose stools per day (range, 4-ority over loperamide. mg (two patients). No toxicity wasFourteen consecuti...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.